Incyte Corp Management Meeting Frames Revenue-Replacement Strategy

Incyte management hosted a dinner highlighting their revenue replacement strategy through clinical execution of the mCALR program and povo in HS. The company targets $3-$4bn in launch revenues by 2030 and is open to M&A deals up to $5bn.

Key Takeaways

• 1.Management maintains high confidence in the mCALR program with Ph3 initiation in 2L ET starting this month and 2L MF pivoting toward a summer end-of-Ph2 meeting.
• 2.Povorcitinib (povo) is targeted at the pre-biologic setting for hidradenitis suppurativa (HS), where 75% of actively treated patients are currently biologic-naive.
• 3.Incyte anticipates seven launches to contribute a combined $3-$4bn in revenue by FY30 to offset future revenue loss.

Table of Contents

• Management views povo as well-positioned in the pre-biologic setting in HS.
• Monitoring pipeline progress.
• Business development an important potential lever.
• Valuation & risks
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Additional disclosures required under the laws and regulations of jurisdictions other than the United States
• Ratings, coverage universe and related definitions
• Global product; distributing entities
• General disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial